Advertisement

Substance Use Disorders

  • A. Benjamin SrivastavaEmail author
  • Steven L. Jaffe
  • Mark S. Gold
Chapter

Abstract

Adolescent substance use disorders are common illnesses that will be encountered in the primary care setting. Though they have been decreasing in prevalence recently, they still manifest in significant public health costs and increase the chance for negative life outcomes. When identification and intervention occur at an early stage, many of the long-term consequences may be mitigated. Thus, identifying, preliminarily treating, and referring to subspecialty treatment when necessary are an important skillset for the primary care provider.

Keywords

Adolescent Addiction Marijuana Alcohol Opioids Substance use disorders Treatment Recovery 

References

  1. 1.
    U.S. Department of Health and Human Services (HHS) Office of the Surgeon General. Facing Addiction in America. The surgeon General’s report on alcohol, drugs, and health. Washington, DC: HHS; 2016.Google Scholar
  2. 2.
    The National Center on Addiction and Substance Abuse at Columbia University. Adolescent substance use: America's #1 public health problem. New York, NY: Columbia University; 2011.Google Scholar
  3. 3.
    Johnston LD, O’Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use 1975–2016: overview. In: Key findings on adolescent drug use. Ann Arbor: Institute for Social Research, The University of Michigan; 2017.Google Scholar
  4. 4.
    Io M, Council NR. Juvenile Crime, Juvenile Justice. Washington, DC: The National Academies Press; 2001. p. 404.Google Scholar
  5. 5.
    Center for Behavioral Health Statistics and Quality. Key substance use and mental health indicators in the United States: Results from the 2015 National Survey on Drug Use and Health. 2016 Contract No.: HHS Publication No. SMA 16-4984.Google Scholar
  6. 6.
    Grucza RA, Agrawal A, Krauss MJ, Bongu J, Plunk AD, Cavazos-Rehg PA, et al. Declining prevalence of marijuana use disorders among adolescents in the United States, 2002 to 2013. J Am Acad Child Adolesc Psychiatry. 2016;55(6):487–94.e6.CrossRefGoogle Scholar
  7. 7.
    U.S. Department of Health and Human Services. E-Cigarette Use Among Youth and Young Adults. A Report of the Surgeon General. Atlanta, GA. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion. In: Office on smoking and health; 2016.Google Scholar
  8. 8.
    Leventhal AM, Strong DR, Kirkpatrick MG, Unger JB, Sussman S, Riggs NR, et al. Association of Electronic Cigarette use with Initiation of combustible tobacco product smoking in early adolescence. JAMA. 2015;314(7):700–7.CrossRefGoogle Scholar
  9. 9.
    Bold KW, Kong G, Camenga DR, Simon P, Cavallo DA, Morean ME, et al. Trajectories of E-cigarette and conventional cigarette use among youth. Pediatrics. 2017;141(1):e20171832.CrossRefGoogle Scholar
  10. 10.
    HIDTA RM. The legalization of marijuana in Colorado: the impact. Kansas: Investigative Support Center Strategic Intelligence Unit; 2016.Google Scholar
  11. 11.
    Mericle AA, Arria AM, Meyers K, Cacciola J, Winters KC, Kirby K. National Trends in adolescent substance use disorders and treatment availability: 2003-2010. J Child Adolesc Subst Abuse. 2015;24(5):255–63.CrossRefGoogle Scholar
  12. 12.
    Koob GF, Volkow ND. Neurobiology of addiction: a neurocircuitry analysis. Lancet Psychiatry. 2016;3(8):760–73.CrossRefGoogle Scholar
  13. 13.
    Miller ML, Hurd YL. Testing the gateway hypothesis. Neuropsychopharmacology. 2017;42(5):985–6.CrossRefGoogle Scholar
  14. 14.
    Kandel D, Faust R. Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiatry. 1975;32(7):923–32.CrossRefGoogle Scholar
  15. 15.
    Nkansah-Amankra S, Minelli M. Gateway hypothesis and early drug use: additional findings from tracking a population-based sample of adolescents to adulthood. Prev Med Rep. 2016;4:134–41.CrossRefGoogle Scholar
  16. 16.
    Tanski S, Garfunkel LC, Duncan PM, Weitzman M, editors. Performing preventive services: a bright futures handbook: American Academy of Pediatrics.; 2010 2010-10-01 00:00:00. p. 212.Google Scholar
  17. 17.
    Herron AJ, Brennan TK. The ASAM essentials of addiction medicine. Philadelphia, PA: Wolters Kluwer; 2015.Google Scholar
  18. 18.
    Levine A, Huang Y, Drisaldi B, Griffin EA Jr, Pollak DD, Xu S, et al. Molecular mechanism for a gateway drug: epigenetic changes initiated by nicotine prime gene expression by cocaine. Sci Transl Med. 2011;3(107):107ra9.CrossRefGoogle Scholar
  19. 19.
    Karami S, Major JM, Calderon S, JK MA. Trends in dextromethorphan cough and cold products: 2000-2015 National Poison Data System intentional abuse exposure calls. Clin Toxicol (Phila). 2017:1–8.Google Scholar
  20. 20.
    Bergen HA, Martin G, Roeger L, Allison S. Perceived academic performance and alcohol, tobacco and marijuana use: longitudinal relationships in young community adolescents. Addict Behav. 2005;30(8):1563–73.CrossRefGoogle Scholar
  21. 21.
    Feighner JP, Robins E, Guze SB, Woodruff RA Jr, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry. 1972;26(1):57–63.CrossRefGoogle Scholar
  22. 22.
    Standridge JB, Adams SM, Zotos AP. Urine drug screening: a valuable office procedure. Am Fam Physician. 2010;81(5):635–40.PubMedGoogle Scholar
  23. 23.
    Bukstein OG, Bernet W, Arnold V, Beitchman J, Shaw J, Benson RS, et al. Practice parameter for the assessment and treatment of children and adolescents with substance use disorders. J Am Acad Child Adolesc Psychiatry. 2005;44(6):609–21.CrossRefGoogle Scholar
  24. 24.
    Conway KP, Swendsen J, Husky MM, He JP, Merikangas KR. Association of Lifetime Mental Disorders and Subsequent Alcohol and illicit drug use: results from the National Comorbidity Survey-Adolescent Supplement. J Am Acad Child Adolesc Psychiatry. 2016;55(4):280–8.CrossRefGoogle Scholar
  25. 25.
    Duperrouzel J, Hawes SW, Lopez-Quintero C, Pacheco-Colon I, Comer J, Gonzalez R. The association between adolescent cannabis use and anxiety: a parallel process analysis. Addict Behav. 2017;78:107–13.CrossRefGoogle Scholar
  26. 26.
    The Center for Adolescent Substance Use Research. The CRAFFT 2.0 Manual. Boston, MA; 2017.Google Scholar
  27. 27.
    D'Amico EJ, Tucker JS, Pedersen ER, Shih RA. Understanding rates of marijuana use and consequences among adolescents in a changing legal landscape. Curr Addict Rep. 2017;4(4):343–9.CrossRefGoogle Scholar
  28. 28.
    Sewell RA, Poling J, Sofuoglu M. The effect of cannabis compared with alcohol on driving. Am J Addict. 2009;18(3):185–93.CrossRefGoogle Scholar
  29. 29.
    Knight JR. The CRAFFT Interview (version 2.0). Boston Children's Hospital Center for Adolescent Substance Abuse Research. 2016.Google Scholar
  30. 30.
    Mitchell SG, Gryczynski J, O'Grady KE, Schwartz RP. SBIRT for adolescent drug and alcohol use: current status and future directions. J Subst Abus Treat. 2013;44(5):463–72.CrossRefGoogle Scholar
  31. 31.
    Stanger C, Lansing AH, Budney AJ. Advances in research on contingency Management for Adolescent Substance use. Child Adolesc Psychiatr Clin N Am. 2016;25(4):645–59.CrossRefGoogle Scholar
  32. 32.
    Kaminer Y, Slesnick N. Evidence-based cognitive-behavioral and family therapies for adolescent alcohol and other substance use disorders. Recent Dev Alcohol. 2005;17:383–405.CrossRefGoogle Scholar
  33. 33.
    Volkow ND, Swanson JM, Evins AE, DeLisi LE, Meier MH, Gonzalez R, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiat. 2016;73(3):292–7.CrossRefGoogle Scholar
  34. 34.
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RSE, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci. 2012;109:E2657–E64.CrossRefGoogle Scholar
  35. 35.
    Hammond CJ. The role of pharmacotherapy in the treatment of adolescent substance use disorders. Child Adolesc Psychiatr Clin N Am. 2016;25(4):685–711.CrossRefGoogle Scholar
  36. 36.
    Naloxone for Treatment of opioid overdose. Insys Development Company, Inc., Arizona, 2016Google Scholar
  37. 37.
    Gray KM, Carpenter MJ, Baker NL, DeSantis SM, Kryway E, Hartwell KJ, Brady KT. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am J Psychiatry. 2012;169(8):805–12.  https://doi.org/10.1176/appi.ajp.2012.12010055.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Quinn PD, Chang Z, Hur K, Gibbons RD, Lahey BB, Rickert ME, et al. ADHD medication and substance-related problems. Am J Psychiatry. 2017;174(9):877–85.CrossRefGoogle Scholar
  39. 39.
    Mansbach RS, Moore RA. Jr formulation considerations for the development of medications with abuse potential. Drug Alcohol Depend. 2006;83S:S15–22.CrossRefGoogle Scholar
  40. 40.
    Friedman RA. Antidepressants' black-box warning — 10 years later. N Engl J Med. 2014;371(18):1666–8.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • A. Benjamin Srivastava
    • 1
    Email author
  • Steven L. Jaffe
    • 2
  • Mark S. Gold
    • 1
  1. 1.Department of PsychiatryWashington University School of MedicineSaint LouisUSA
  2. 2.Department of PsychiatryEmory University School of MedicineAtlantaUSA

Personalised recommendations